A new experimental drug delivery system shows potential to reverse osteoarthritis in animal subjects within weeks. Developed by researchers at the University of Colorado (UC) Boulder, the therapy involves a single injection into damaged joints, stimulating the body's own cartilage and bone cells to initiate repair.
This approach moves beyond current treatments, which primarily focus on pain management or surgical joint replacement. Chemical and biological engineer Stephanie Bryant stated the goal is not just to treat symptoms but to eliminate the disease. The team is preparing for phase two animal trials to gather safety and toxicology data before human clinical trials can commence. The research is supported by the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, funded by the US Department of Health and Human Services' ARPA-H.